IntoCell, Inc. Logo

IntoCell, Inc.

Develops platform technologies for Antibody-Drug Conjugates (ADCs) for oncology.

287840 | KO

Overview

Corporate Details

ISIN(s):
KR7287840003
LEI:
Country:
South Korea
Address:
대전광역시 대덕구 신일동로 101, 대전광역시

Description

IntoCell, Inc. is a biotechnology company specializing in the research and development of platform technologies for Antibody-Drug Conjugates (ADCs). The company's core focus is on creating novel biopharmaceuticals, primarily for oncology applications. IntoCell develops proprietary technologies, including its OHPAS™ linker and Payload Modification Technology (PMT™), which are designed to improve the stability, efficacy, and safety of ADC therapeutics. The company advances its own drug pipeline and also collaborates with other pharmaceutical companies through technology transfer and partnership agreements to commercialize its ADC platforms.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
투자판단관련주요경영사항(임상시험계획승인신청) (ITC6146RO의 한국 MFDS 제1상 임상시험계획 승인신청)
Korean 8.8 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 758.7 KB
2025-07-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.3 KB
2025-07-09 00:00
투자판단관련주요경영사항 (ADC 플랫폼 기술에 대한 실시권 계약 해지)
Korean 6.6 KB
2025-07-07 00:00
주식등의대량보유상황보고서(일반)
Korean 146.8 KB
2025-06-23 00:00
주식등의대량보유상황보고서(약식)
Korean 63.6 KB
2025-05-30 00:00
주식등의대량보유상황보고서(약식)
Korean 73.6 KB
2025-05-29 00:00
주식등의대량보유상황보고서(일반)
Korean 185.8 KB
2025-05-29 00:00
주식등의대량보유상황보고서(약식)
Korean 65.6 KB
2025-05-28 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-28 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-28 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB

Automate Your Workflow. Get a real-time feed of all IntoCell, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IntoCell, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IntoCell, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.